HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - Pharmacological approaches

Jr Adams K.F., K. L. Baughman, W. G. Dec, U. Elkayam, A. D. Forker, M. Gheorghiade, D. Hermann, M. A. Konstam, P. Liu, B. M. Massie, J. H. Patterson, M. A. Silver, W. Stevenson, A. M. Feldman, J. N. Cohn, G. S. Francis, B. Greenberg, M. A. Konstam, C. Leier, B. H. Lorell & 9 others M. Packer, B. Pitt, E. H. Sonnenblick, J. Strobeck, R. Walsh, S. Yusuf, G. A J Reigger, H. Bouzo, P. Petr

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background. The renin-angiotensin system plays an important part in the pathogenesis of congestive heart failure (CHF). This study evaluated the effect of an angiotensin II type I receptor antagonist on exercise tolerance and symptoms of CHF. Methods and Results. In this multicenter, double-blind, parallel-group study, 844 patients with CHF were randomized to 12 weeks treatment with placebo (n=211) or candesartan cilexetil 4 mg (n=208), 8 mg (n=212), or 16 mg (n=213) after a 4 week placebo run-in period. Changes in exercise time, Dyspnea Fatigue Index score, NYHA functional class, and cardiothoracic ratio were determined. Candesartan cilexetil produced a dose-related improvement in exercise time. For the intention-to-treat population, the increase produced by candesartan cilexetil 16 mg was significantly greater than that produced by placebo (47.2 versus 30.8 seconds, P=0.0463). All doses of candesartan cilexetil significantly improved the Dyspnea Fatigue Index score relative to placebo. NYHA class improved more frequently in the candesartan cilexetil groups: the difference relative to placebo were not significant. The decrease in cardiothoracic ratio with candesartan 4 to 6 mg was small but statistically significant compared with placebo (all P<0.05). In all candesartan cilexetil groups, plasma renin activity and angiotensin II levels increased from baseline and aldosterone levels decreased in the 8- and 16-mg treatment groups. Candesartan cilexetil was well tolerated at all doses. Conclusions. In summary, treatment with candesartan cilexetil demonstrated significant improvements in exercise tolerance, cardiothoracic ratio, and symptoms and signs of CHF and was well tolerated.

Original languageEnglish (US)
JournalCongestive Heart Failure
Volume6
Issue number1
StatePublished - 2000

Fingerprint

Left Ventricular Dysfunction
Heart Failure
Pharmacology
Guidelines
Placebos
Exercise Tolerance
Dyspnea
Fatigue
Exercise
Angiotensin I
candesartan cilexetil
Angiotensin Receptor Antagonists
Renin-Angiotensin System
Aldosterone
Renin
Angiotensin II
Signs and Symptoms
Therapeutics
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Adams K.F., J., Baughman, K. L., Dec, W. G., Elkayam, U., Forker, A. D., Gheorghiade, M., ... Petr, P. (2000). HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - Pharmacological approaches. Congestive Heart Failure, 6(1).

HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - Pharmacological approaches. / Adams K.F., Jr; Baughman, K. L.; Dec, W. G.; Elkayam, U.; Forker, A. D.; Gheorghiade, M.; Hermann, D.; Konstam, M. A.; Liu, P.; Massie, B. M.; Patterson, J. H.; Silver, M. A.; Stevenson, W.; Feldman, A. M.; Cohn, J. N.; Francis, G. S.; Greenberg, B.; Konstam, M. A.; Leier, C.; Lorell, B. H.; Packer, M.; Pitt, B.; Sonnenblick, E. H.; Strobeck, J.; Walsh, R.; Yusuf, S.; Reigger, G. A J; Bouzo, H.; Petr, P.

In: Congestive Heart Failure, Vol. 6, No. 1, 2000.

Research output: Contribution to journalArticle

Adams K.F., J, Baughman, KL, Dec, WG, Elkayam, U, Forker, AD, Gheorghiade, M, Hermann, D, Konstam, MA, Liu, P, Massie, BM, Patterson, JH, Silver, MA, Stevenson, W, Feldman, AM, Cohn, JN, Francis, GS, Greenberg, B, Konstam, MA, Leier, C, Lorell, BH, Packer, M, Pitt, B, Sonnenblick, EH, Strobeck, J, Walsh, R, Yusuf, S, Reigger, GAJ, Bouzo, H & Petr, P 2000, 'HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - Pharmacological approaches', Congestive Heart Failure, vol. 6, no. 1.
Adams K.F., Jr ; Baughman, K. L. ; Dec, W. G. ; Elkayam, U. ; Forker, A. D. ; Gheorghiade, M. ; Hermann, D. ; Konstam, M. A. ; Liu, P. ; Massie, B. M. ; Patterson, J. H. ; Silver, M. A. ; Stevenson, W. ; Feldman, A. M. ; Cohn, J. N. ; Francis, G. S. ; Greenberg, B. ; Konstam, M. A. ; Leier, C. ; Lorell, B. H. ; Packer, M. ; Pitt, B. ; Sonnenblick, E. H. ; Strobeck, J. ; Walsh, R. ; Yusuf, S. ; Reigger, G. A J ; Bouzo, H. ; Petr, P. / HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - Pharmacological approaches. In: Congestive Heart Failure. 2000 ; Vol. 6, No. 1.
@article{0f5bedf407744259a9f6075f93495f36,
title = "HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - Pharmacological approaches",
abstract = "Background. The renin-angiotensin system plays an important part in the pathogenesis of congestive heart failure (CHF). This study evaluated the effect of an angiotensin II type I receptor antagonist on exercise tolerance and symptoms of CHF. Methods and Results. In this multicenter, double-blind, parallel-group study, 844 patients with CHF were randomized to 12 weeks treatment with placebo (n=211) or candesartan cilexetil 4 mg (n=208), 8 mg (n=212), or 16 mg (n=213) after a 4 week placebo run-in period. Changes in exercise time, Dyspnea Fatigue Index score, NYHA functional class, and cardiothoracic ratio were determined. Candesartan cilexetil produced a dose-related improvement in exercise time. For the intention-to-treat population, the increase produced by candesartan cilexetil 16 mg was significantly greater than that produced by placebo (47.2 versus 30.8 seconds, P=0.0463). All doses of candesartan cilexetil significantly improved the Dyspnea Fatigue Index score relative to placebo. NYHA class improved more frequently in the candesartan cilexetil groups: the difference relative to placebo were not significant. The decrease in cardiothoracic ratio with candesartan 4 to 6 mg was small but statistically significant compared with placebo (all P<0.05). In all candesartan cilexetil groups, plasma renin activity and angiotensin II levels increased from baseline and aldosterone levels decreased in the 8- and 16-mg treatment groups. Candesartan cilexetil was well tolerated at all doses. Conclusions. In summary, treatment with candesartan cilexetil demonstrated significant improvements in exercise tolerance, cardiothoracic ratio, and symptoms and signs of CHF and was well tolerated.",
author = "{Adams K.F.}, Jr and Baughman, {K. L.} and Dec, {W. G.} and U. Elkayam and Forker, {A. D.} and M. Gheorghiade and D. Hermann and Konstam, {M. A.} and P. Liu and Massie, {B. M.} and Patterson, {J. H.} and Silver, {M. A.} and W. Stevenson and Feldman, {A. M.} and Cohn, {J. N.} and Francis, {G. S.} and B. Greenberg and Konstam, {M. A.} and C. Leier and Lorell, {B. H.} and M. Packer and B. Pitt and Sonnenblick, {E. H.} and J. Strobeck and R. Walsh and S. Yusuf and Reigger, {G. A J} and H. Bouzo and P. Petr",
year = "2000",
language = "English (US)",
volume = "6",
journal = "Prevention and Management of Congestive Heart Failure",
issn = "1527-5299",
publisher = "Le Jacq Communications, Inc.",
number = "1",

}

TY - JOUR

T1 - HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction - Pharmacological approaches

AU - Adams K.F., Jr

AU - Baughman, K. L.

AU - Dec, W. G.

AU - Elkayam, U.

AU - Forker, A. D.

AU - Gheorghiade, M.

AU - Hermann, D.

AU - Konstam, M. A.

AU - Liu, P.

AU - Massie, B. M.

AU - Patterson, J. H.

AU - Silver, M. A.

AU - Stevenson, W.

AU - Feldman, A. M.

AU - Cohn, J. N.

AU - Francis, G. S.

AU - Greenberg, B.

AU - Konstam, M. A.

AU - Leier, C.

AU - Lorell, B. H.

AU - Packer, M.

AU - Pitt, B.

AU - Sonnenblick, E. H.

AU - Strobeck, J.

AU - Walsh, R.

AU - Yusuf, S.

AU - Reigger, G. A J

AU - Bouzo, H.

AU - Petr, P.

PY - 2000

Y1 - 2000

N2 - Background. The renin-angiotensin system plays an important part in the pathogenesis of congestive heart failure (CHF). This study evaluated the effect of an angiotensin II type I receptor antagonist on exercise tolerance and symptoms of CHF. Methods and Results. In this multicenter, double-blind, parallel-group study, 844 patients with CHF were randomized to 12 weeks treatment with placebo (n=211) or candesartan cilexetil 4 mg (n=208), 8 mg (n=212), or 16 mg (n=213) after a 4 week placebo run-in period. Changes in exercise time, Dyspnea Fatigue Index score, NYHA functional class, and cardiothoracic ratio were determined. Candesartan cilexetil produced a dose-related improvement in exercise time. For the intention-to-treat population, the increase produced by candesartan cilexetil 16 mg was significantly greater than that produced by placebo (47.2 versus 30.8 seconds, P=0.0463). All doses of candesartan cilexetil significantly improved the Dyspnea Fatigue Index score relative to placebo. NYHA class improved more frequently in the candesartan cilexetil groups: the difference relative to placebo were not significant. The decrease in cardiothoracic ratio with candesartan 4 to 6 mg was small but statistically significant compared with placebo (all P<0.05). In all candesartan cilexetil groups, plasma renin activity and angiotensin II levels increased from baseline and aldosterone levels decreased in the 8- and 16-mg treatment groups. Candesartan cilexetil was well tolerated at all doses. Conclusions. In summary, treatment with candesartan cilexetil demonstrated significant improvements in exercise tolerance, cardiothoracic ratio, and symptoms and signs of CHF and was well tolerated.

AB - Background. The renin-angiotensin system plays an important part in the pathogenesis of congestive heart failure (CHF). This study evaluated the effect of an angiotensin II type I receptor antagonist on exercise tolerance and symptoms of CHF. Methods and Results. In this multicenter, double-blind, parallel-group study, 844 patients with CHF were randomized to 12 weeks treatment with placebo (n=211) or candesartan cilexetil 4 mg (n=208), 8 mg (n=212), or 16 mg (n=213) after a 4 week placebo run-in period. Changes in exercise time, Dyspnea Fatigue Index score, NYHA functional class, and cardiothoracic ratio were determined. Candesartan cilexetil produced a dose-related improvement in exercise time. For the intention-to-treat population, the increase produced by candesartan cilexetil 16 mg was significantly greater than that produced by placebo (47.2 versus 30.8 seconds, P=0.0463). All doses of candesartan cilexetil significantly improved the Dyspnea Fatigue Index score relative to placebo. NYHA class improved more frequently in the candesartan cilexetil groups: the difference relative to placebo were not significant. The decrease in cardiothoracic ratio with candesartan 4 to 6 mg was small but statistically significant compared with placebo (all P<0.05). In all candesartan cilexetil groups, plasma renin activity and angiotensin II levels increased from baseline and aldosterone levels decreased in the 8- and 16-mg treatment groups. Candesartan cilexetil was well tolerated at all doses. Conclusions. In summary, treatment with candesartan cilexetil demonstrated significant improvements in exercise tolerance, cardiothoracic ratio, and symptoms and signs of CHF and was well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0034468304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034468304&partnerID=8YFLogxK

M3 - Article

VL - 6

JO - Prevention and Management of Congestive Heart Failure

JF - Prevention and Management of Congestive Heart Failure

SN - 1527-5299

IS - 1

ER -